ME03723B - 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori - Google Patents
2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтoriInfo
- Publication number
- ME03723B ME03723B MEP-2018-267A MEP2018267A ME03723B ME 03723 B ME03723 B ME 03723B ME P2018267 A MEP2018267 A ME P2018267A ME 03723 B ME03723 B ME 03723B
- Authority
- ME
- Montenegro
- Prior art keywords
- difluoromethyl
- difluoro
- amino
- tetrahydropyridin
- fluorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (13)
1. Jedinjenje formule I u kojoj je Ar odabran iz grupe koju čine fenil, piridil, pirimidil, pirazinil, imidazolil, pirazolil, tiazolil, oksazolil, izoksazolil, i gde je Ar opciono supstituisani jednim ili više supstituenata odabran od halogena, CN, C1-C6 alkila, C2-C6 alkenila, C2-C6 alkinila, C1-C6 fluoroalkila ili C1-C6 alkoksi; iR1 je vodonik, halogen, C1-C3 fluoroalkil ili C1-C3 alkil;ili njegova farmaceutski prihvatljiva so.
2.Jedinjenje prema zahtevu 1, gde je to jedinjenje formule Ia ili njegova farmaceutski prihvatljiva so.
3.Jedinjenje prema zahtevu 1 ili 2, gde R1 je F ili H.
4.Jedinjenje prema zahtevu 1 ili 2, gde je Ar opciono supstituisan jednim ili više F, Cl, Br, CN, C1-C3 alkila, C1-C3 fluoroalkila ili C1-C3 alkoksi.
5.Jedinjenje prema bilo kom od zahteva 1-4, gde je Ar opciono supstituisani piridil.
6.Jedinjenje prema bilo kom od zahteva 1-4, gde je Ar opciono supstituisani pirimidil.
7.Jedinjenje prema bilo kom od zahteva 1-4, gde je Ar opciono supstituisani pirazinil.
8.Jedinjenje prema bilo kom od zahteva 1-4, gde je Ar opciono supstituisani oksazolil.
9.Jedinjenje prema bilo kom od zahteva 1-4, gde je Ar opciono supstituisani tiazolil.
10.Jedinjenje prema zahtevu 1, gde je to jedinjenje odabrano iz grupe koju čine: (S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-hloropikolinamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-fluoropikolinamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-metoksipirazin-2-karboksamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-2-metiloksazol-4-karboksamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-metoksipikolinamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-(difluorometil)pirazin-2-karboksamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-cijanopikolinamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-4- metiltiazol-2-karboksamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-metoksipirimidin-2-karboksamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-metoksi-3-metilpirazin-2-karboksamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-cijano-3-metilpikolinamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-bromopikolinamid,(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-(metoksi-d3)pikolinamid i(S)-N-(3-(6-amino-2-(difluorometil)-3,3-difluoro-2,3,4,5-tetrahidropiridin-2-il)-4-fluorofenil)-5-(metoksi-d3)pirazin-2-karboksamid;ili njegova farmaceutski prihvatljiva so.
11.Farmaceutska kombinacija koja obuhvata jedinjenje prema bilo kom od zahteva 1-10 i farmaceutski prihvatljiv nosač.
12.Jedinjenje prema bilo kom od zahteva 1-10 za upotrebu u terapiji.
13.Jedinjenje prema bilo kom od zahteva 1-10 za upotrebu u lečenju bolesti odabrane od Achajmerove bolesti (porodična ili sporadična), prekliničke Achajmerove bolesti, prodromalne Achajmerove bolesti, blagog kognitivnog oštećenja, Daunovog sindroma i cerebralne amiloidne angiopatije.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400648 | 2014-11-10 | ||
| DKPA201500447 | 2015-08-07 | ||
| PCT/EP2015/076015 WO2016075063A1 (en) | 2014-11-10 | 2015-11-09 | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
| EP15805109.4A EP3218365B1 (en) | 2014-11-10 | 2015-11-09 | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03723B true ME03723B (me) | 2021-04-20 |
Family
ID=54783558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2018-267A ME03723B (me) | 2014-11-10 | 2015-11-09 | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori |
Country Status (44)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| HK1253372A1 (zh) * | 2015-08-12 | 2019-06-14 | H‧隆德贝克有限公司 | 作为bace1抑制剂的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3，4，5，6-四氢吡啶 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190081A1 (ar) * | 2016-10-13 | 2019-04-11 | Novartis Ag | مشتق أوكسازين للاستخدام في علاج أو الوقاية من اعتلال وعائي دماغي نشواني |
| MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
| EP3532064B1 (en) | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| TW201829394A (zh) | 2016-12-21 | 2018-08-16 | 丹麥商Ｈ 朗德貝克公司 | 作為ｂａｃｅ１抑制劑之６-胺基-５-氟-５-（氟甲基）-２，３，４，５-四氫吡啶-２-基-苯基-５-（甲氧基-ｄ）-吡-２-甲醯胺及其氟化衍生物 |
| SG11202005361RA (en) | 2017-12-14 | 2020-07-29 | H Lundbeck As | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| EP3728250A1 (en) | 2017-12-20 | 2020-10-28 | H. Lundbeck A/S | PYRAZOLO[3,4-beta]PYRIDINES AND IMIDAZO[1,5-beta]PYRIDAZINES AS PDE1 INHIBITORS |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0210391A (pt) | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| GB0124928D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| KR101058292B1 (ko) | 2002-02-12 | 2011-08-22 | 글락소스미스클라인 엘엘씨 | Ｐ38 억제제로 유용한 니코틴아미드 유도체 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| WO2011154431A1 (en) * | 2010-06-09 | 2011-12-15 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| MX2013008111A (es) | 2011-01-12 | 2013-10-30 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de transtornos neurologicos. |
| CN106117193B (zh) | 2011-01-13 | 2019-09-13 | 诺华股份有限公司 | 新的杂环衍生物及其在神经性疾病治疗中的应用 |
| US8754075B2 (en) * | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| CN103608345A (zh) | 2011-04-26 | 2014-02-26 | 盐野义制药株式会社 | 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂 |
| JP2014516063A (ja) | 2011-06-07 | 2014-07-07 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂａｃｅ１及び／又はｂａｃｅ２阻害剤としてのハロゲン−アルキル−１，３オキサジン |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| EP2827857A4 (en) | 2012-03-20 | 2016-03-30 | Elan Pharm Inc | SPIROCYCLIC DIHYDRO-THIAZINE AND INHIBITORS OF BACE DIHYDRO-OXAZINE AND COMPOSITIONS AND USES THEREOF |
| WO2014056816A1 (en) | 2012-10-10 | 2014-04-17 | F. Hoffmann-La Roche Ag | COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR |
| WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
| WO2014134341A1 (en) | 2013-03-01 | 2014-09-04 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| TWI639607B (zh) | 2013-06-18 | 2018-11-01 | 美國禮來大藥廠 | Ｂａｃｅ抑制劑 |
| MX2016010777A (es) | 2014-02-19 | 2016-10-26 | H Lundbeck As | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer. |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| TW201717948A (zh) | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| HK1253372A1 (zh) | 2015-08-12 | 2019-06-14 | H‧隆德贝克有限公司 | 作为bace1抑制剂的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3，4，5，6-四氢吡啶 |
| TW201829394A (zh) | 2016-12-21 | 2018-08-16 | 丹麥商Ｈ 朗德貝克公司 | 作為ｂａｃｅ１抑制劑之６-胺基-５-氟-５-（氟甲基）-２，３，４，５-四氫吡啶-２-基-苯基-５-（甲氧基-ｄ）-吡-２-甲醯胺及其氟化衍生物 |
-
2015
- 2015-10-25 JO JOP/2015/0260A patent/JO3458B1/ar active
- 2015-11-05 US US14/933,301 patent/US9346797B1/en not_active Expired - Fee Related
- 2015-11-09 RS RS20181321A patent/RS57946B1/sr unknown
- 2015-11-09 HU HUE15805109A patent/HUE040304T2/hu unknown
- 2015-11-09 LT LTEP15805109.4T patent/LT3218365T/lt unknown
- 2015-11-09 TR TR2018/16427T patent/TR201816427T4/tr unknown
- 2015-11-09 MX MX2017006049A patent/MX2017006049A/es unknown
- 2015-11-09 TN TN2017000144A patent/TN2017000144A1/en unknown
- 2015-11-09 ME MEP-2018-267A patent/ME03723B/me unknown
- 2015-11-09 CA CA2965563A patent/CA2965563A1/en not_active Abandoned
- 2015-11-09 CN CN201580060803.9A patent/CN107074836B/zh not_active Expired - Fee Related
- 2015-11-09 KR KR1020177012442A patent/KR20170081184A/ko not_active Withdrawn
- 2015-11-09 BR BR112017009583A patent/BR112017009583A2/pt not_active Application Discontinuation
- 2015-11-09 EP EP18198764.5A patent/EP3461483A1/en not_active Withdrawn
- 2015-11-09 RU RU2017116196A patent/RU2017116196A/ru not_active Application Discontinuation
- 2015-11-09 EP EP15805109.4A patent/EP3218365B1/en active Active
- 2015-11-09 DK DK15805109.4T patent/DK3218365T3/en active
- 2015-11-09 TW TW104136839A patent/TWI690318B/zh not_active IP Right Cessation
- 2015-11-09 UA UAA201704639A patent/UA119576C2/uk unknown
- 2015-11-09 CR CR20170186A patent/CR20170186A/es unknown
- 2015-11-09 EA EA201790818A patent/EA032339B1/ru not_active IP Right Cessation
- 2015-11-09 SM SM20180570T patent/SMT201800570T1/it unknown
- 2015-11-09 US US15/524,546 patent/US10045974B2/en not_active Expired - Fee Related
- 2015-11-09 PE PE2017000825A patent/PE20170946A1/es unknown
- 2015-11-09 PT PT15805109T patent/PT3218365T/pt unknown
- 2015-11-09 JP JP2017525010A patent/JP6629320B2/ja not_active Expired - Fee Related
- 2015-11-09 HR HRP20181698TT patent/HRP20181698T1/hr unknown
- 2015-11-09 AU AU2015345258A patent/AU2015345258B2/en not_active Expired - Fee Related
- 2015-11-09 ES ES15805109.4T patent/ES2694860T3/es active Active
- 2015-11-09 GE GEAP201514485A patent/GEP20196949B/en unknown
- 2015-11-09 PL PL15805109T patent/PL3218365T3/pl unknown
- 2015-11-09 WO PCT/EP2015/076015 patent/WO2016075063A1/en not_active Ceased
- 2015-11-09 MA MA40955A patent/MA40955B1/fr unknown
- 2015-11-09 SG SG11201703547XA patent/SG11201703547XA/en unknown
- 2015-11-09 GE GEAP201814485A patent/GEAP201814485A/en unknown
- 2015-11-09 SI SI201530464T patent/SI3218365T1/sl unknown
-
2017
- 2017-04-20 ZA ZA2017/02797A patent/ZA201702797B/en unknown
- 2017-05-03 IL IL252089A patent/IL252089B/en not_active IP Right Cessation
- 2017-05-03 CO CONC2017/0004465A patent/CO2017004465A2/es unknown
- 2017-05-04 CL CL2017001112A patent/CL2017001112A1/es unknown
- 2017-05-05 PH PH12017500841A patent/PH12017500841A1/en unknown
- 2017-05-09 EC ECIEPI201728459A patent/ECSP17028459A/es unknown
- 2017-05-09 NI NI201700055A patent/NI201700055A/es unknown
- 2017-05-09 DO DO2017000117A patent/DOP2017000117A/es unknown
- 2017-05-09 SV SV2017005435A patent/SV2017005435A/es unknown
- 2017-05-10 GT GT201700099A patent/GT201700099A/es unknown
-
2018
- 2018-08-09 US US16/059,715 patent/US10603310B2/en not_active Expired - Fee Related
- 2018-11-13 CY CY20181101200T patent/CY1120846T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| MX2016009403A (es) | Compuestos heterociclicos. | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| HRP20210447T1 (hr) | Piridinski spoj | |
| NZ630124A (en) | Estrogen receptor modulators and uses thereof | |
| HUE054454T2 (hu) | (S)-6-((1-Acetilpiperidin-4-il)amino)-N-(3-(3,4-dihidroizokinolin-2(1H)-il)-2- hidroxipropil)pirimidin-4-karboxamid kristályos sói | |
| EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| HRP20170873T1 (hr) | Monociklički derivat piridina | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| RU2018119102A (ru) | Терапевтическое средство для лечения рака молочной железы | |
| PE20160666A1 (es) | Derivados de etinilo | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| NZ598754A (en) | Therapeutic agent for anxiety disorders | |
| PH12016501645A1 (en) | Aminopyrazolone derivative | |
| NZ707832A (en) | 2-pyridone compound | |
| MX349697B (es) | Nuevo derivado de fenilpiridina y farmaco que contiene el mismo. | |
| MY170241A (en) | Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof |